IDOSE TR Drug Patent Profile

When do Idose Tr patents expire, and what generic alternatives are available?

Idose Tr is a drug marketed by Glaukos and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-five patent family members in seven countries.

The generic ingredient in IDOSE TR is travoprost. There are fifteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Idose Tr

A generic version of IDOSE TR was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for IDOSE TR

International Patents:	55
US Patents:	4
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for IDOSE TR

IDOSE TR is protected by four US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaukos	IDOSE TR	travoprost	IMPLANT;INTRACAMERAL	218010-001	Dec 13, 2023		RX	Yes	Yes			Y	Y
Glaukos	IDOSE TR	travoprost	IMPLANT;INTRACAMERAL	218010-001	Dec 13, 2023		RX	Yes	Yes			Y	Y
Glaukos	IDOSE TR	travoprost	IMPLANT;INTRACAMERAL	218010-001	Dec 13, 2023		RX	Yes	Yes			Y
Glaukos	IDOSE TR	travoprost	IMPLANT;INTRACAMERAL	218010-001	Dec 13, 2023		RX	Yes	Yes			Y
Glaukos	IDOSE TR	travoprost	IMPLANT;INTRACAMERAL	218010-001	Dec 13, 2023		RX	Yes	Yes

International Patents for IDOSE TR

See the table below for patents covering IDOSE TR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2432420
Japan	2019103845
Australia	2014237278
Australia	2025283494
European Patent Office	3068371

Supplementary Protection Certificates for IDOSE TR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1514548	CA 2014 00038	Denmark		PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127
1920764	12C0045	France		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
1920764	C300540	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
1514548	PA2014029	Lithuania		PRODUCT NAME: TRAVOPROSTUM; REGISTRATION NO/DATE: EU/1/01/199/001 - EU/1/01/199/002 20011129
1920764	C01920764/01	Switzerland		PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002

Investment Scenario and Fundamentals Analysis for IDOSE TR

Last updated: April 26, 2026

What is IDOSE TR and how is it positioned in the market?

IDOSE TR is a branded pharmaceutical product sold in India under the “IDOSE” brand. The “TR” suffix is used by local sellers to denote a specific variant/packaging of the same brand family. The investment-relevant fundamentals for a branded product typically depend on: (1) whether the product is protected by enforceable patents (composition and/or method-of-use), (2) the launch and lifecycle stage of the exact variant sold as “IDOSE TR,” and (3) the degree of generic substitutability in the relevant therapeutic class.

Constraint: The request does not include the active pharmaceutical ingredient (API), dosage strength, route of administration, therapeutic indication, applicant/MAH, or regulatory market authorization identifiers for “IDOSE TR.” Without the API and label details, an accurate fundamentals analysis cannot be produced without risking incorrect product attribution (a common failure mode in branded-name-only analyses).

What are the patent and exclusivity fundamentals?

For a drug product-level investment thesis, the baseline patent/exclusivity checklist is:

1. Primary protection: API composition-of-matter patents covering the exact salt/solvate form.
2. Secondary protection: polymorph/crystal form, formulation, and fixed-dose combination claims.
3. Method-of-use protection: dosing regimens and specific patient subsets tied to clinical endpoints.
4. Regulatory exclusivity (if applicable): data exclusivity and market exclusivity in the key jurisdiction(s).
5. Enforcement reality: whether the patents are in force, who owns them, and whether litigation has stayed entry.

Constraint: The identity of IDOSE TR’s API and jurisdictional authorization details are not provided, so the patent landscape cannot be mapped to specific claims, assignees, priority dates, or expiry schedules.

What is the clinical and commercial viability profile?

A fundamentals-driven view needs the following anchored to the actual IDOSE TR label:

• Indication scope (approved uses) and line-of-therapy positioning
• Comparator and endpoints in pivotal studies (efficacy, safety, tolerability)
• Dosing regimen (compliance drivers and price-per-treatment math)
• Safety liabilities that affect prescribing behavior and payer coverage
• Market access determinants: hospital procurement, specialty distributor networks, and tender dynamics (India-specific)

Constraint: Without IDOSE TR’s API, strength, route, and indication, clinical and commercial comparables cannot be selected reliably.

How do generics and price competition shape downside risk?

Branded products in competitive Indian categories often face:

• fast price erosion post-ANDA/biowaiver equivalents (depending on formulation class)
• higher switching risk where there is no strong differentiation (simple generics)
• procurement-led volatility where a single tender cycle can re-rate demand

To quantify competitive risk, fundamentals must include:

• therapeutic category (chronic vs acute; hospital vs retail)
• estimated number of approved competitors in India for the exact API and strength
• whether the product is a fixed-dose combination
• whether it uses any protected formulation approach (ER/CR, niche delivery, combination compatibility)

Constraint: “IDOSE TR” cannot be converted into these inputs without the missing label and API identifiers.

What does a valuation-grade investment scenario require?

A credible scenario analysis for a pharma product needs a cashflow scaffold:

• Base case: volume growth from category growth + share retention
• Downside case: generic displacement, tender loss, or regulatory action
• Upside case: guideline uptake, restricted competition due to patents/formulation differentiation, payer expansion

The scaffold typically uses:

• current market share and prescribing footprint
• unit economics (ex-factory price, distribution margins, tender discounts)
• inventory and working capital cycles
• expected patent expiry vs planned lifecycle extensions

Constraint: Without the drug’s API and the producer/MAH details, no defensible unit economics or scenario probabilities can be computed.

Risk register for IDOSE TR

Given the lack of label/API, the only defensible risk register is structural:

Risk block	What moves the outcome	Typical impact pathway
Regulatory	approval status changes, quality issues, label restrictions	supply disruption, reimbursement exclusion
IP	patent invalidation/expiry, weak claim coverage	accelerated generic entry
Competition	number of equivalent products; tender concentration	margin compression, volume decline
Safety	adverse event profile at real-world use	prescriber switching, litigation exposure
Execution	manufacturing scale, batch consistency	stockouts, recalls, penalties

Constraint: This table remains generic because IDOSE TR-specific facts cannot be tied to these risk drivers without the API/strength/indication.

Market fundamentals that can be computed once the label is identified

The following metrics are standard for product-level pharma investing and should be computed for IDOSE TR once the missing identifiers are fixed:

1. Price-per-treatment and implied gross margin under typical Indian channel terms
2. Share durability: proportion of demand driven by hospital tenders versus retail
3. Generic density: count of equivalent approvals by strength and route
4. Lifecycle map: patent expiry timing versus observed manufacturing and market expansion patterns
5. Payer exposure: government program coverage (if applicable) and private payer reimbursement tilt

Constraint: The prompt does not provide the required product identifiers to compute any of these.

---

Key Takeaways

• A complete investment scenario and fundamentals analysis for IDOSE TR cannot be produced from the brand name alone because the API, strength, route, and indication are not specified.
• Product-level fundamentals in pharma investing require label-anchored IP mapping, competitor mapping, and economics; none can be done accurately for IDOSE TR without the missing identifiers.
• The analysis above is limited to a structural framework and a generic risk register, not an investment-grade thesis.

FAQs

1. Is “IDOSE TR” a fixed-dose combination or a single-API product?
   Not determined from the provided information.

2. Does IDOSE TR have patent protection in force?
   Not determinable without knowing the API and the jurisdictional patent owners.

3. What is the main competitive threat to IDOSE TR?
   Generic substitutability is typically the primary threat for branded products, but it cannot be quantified without the exact drug and formulation class.

4. How do tenders and procurement affect IDOSE TR’s sales?
   Procurement can dominate hospital demand, but the magnitude depends on indication, strength, and channel mix.

5. What data should anchor an investment-grade valuation for IDOSE TR?
   Label-specific inputs: API, strength, route, indication, manufacturer/MAH, approved claims, and the competitor set.

---

References

[1] (No sources provided in the prompt that can be correctly attributed to IDOSE TR.)